Si può desiderare di provare un trattamento naturale disfunzione erettile come un diverso per i problemi di costruzione. Al giorno d oggi ci sono diverse terapie sul mercato, ma un trattamento naturale disfunzione erettile è stato confermato qualche ora e ora di nuovo per dare risultati efficienti e permanenti. Cos è la disfunzione sessuale? L incapacità di sviluppare o sostenere una costruzione abbastanza lungo per fare l amore è chiamato disfunzione erettile, ED https://farmacia-senzaricetta.it/ o (maschio) problemi di erezione. Tutti gli uomini possono avere problemi di costruzione di volta in volta e gli scienziati considerano ED essere presenti se si verificano problemi di costruzione almeno il 25% del tempo. Alcuni fatti duri: ED Può essere dovuto a problemi emotivi. Stress, pressione, giltiness, depressione, bassa autostima e ansia prestazioni può essere la causa dei vostri problemi di costruzione. La ricerca ha confermato che il 90 per cento della disfunzione erettile è fisica in origine, non emotiva. L impotenza colpisce la maggior parte degli uomini durante la loro vita e può essere dovuto a troppo colesterolo, problemi cardiaci, diabete, ipertensione, fumo o alcol. Alcuni rimedi possono essere la ragione. Le questioni legate al movimento sono collegate. Se ti occupi dei tuoi problemi di movimento, hai piu possibilita di risolvere questo problema. Qui ci sono 5 consigli facili su come aumentare la circolazione: 1. Mangia i pasti giusti. Questo ti rendera il flusso sanguigno ovvio. Una grande parte di rimanere sani e anche mantenere il flusso sanguigno ovvio è legato al vostro piano di alimentazione quotidiana e quello che si mangia. Una buona cura per la disfunzione erettile è mangiare un piano a basso contenuto di grassi e grande alimentazione di fibre. Mangiare fibre tutti i giorni e questo viene scoperto in prodotti cerealicoli cereali integrali, frutta e verdura. Evitare il più possibile pasti pronti o pasti non sani. 2. Wonder herbal rimedi. Molti rimedi vegetali per ED eseguire bene come possono migliorare il movimento. Hanno molto meno reazioni avverse rispetto ai farmaci convenzionali e si svolgono in modo efficiente per migliorare hardons e la forza, troppo. Erbe naturali come Ginkgo Biloba sono utilizzati come una strategia per ED. Gli specialisti di erboristeria credono anche che le spezie o le erbe come noce moscata, portano al movimento intorno al corpo, tra cui il pene. 3. Vitamine naturali vitali. Gli scienziati sanitari hanno scoperto che una mancanza di supplemento è tipico tra gli uomini con ED in particolare vitamina A. Se si ha una mancanza del nutriente ossido di zinco, Questo è stato confermato per portare alla disfunzione erettile. Queste inadeguatezze derivano dal fatto che molti valori nutrizionali in quello che mangiamo piano non sono sufficienti. Aggiungere al vostro fabbisogno di nutrienti aumenterà la circolazione del sistema e migliorare questa condizione. Gli integratori alimentari sono completamente naturali, quindi non dovrete preoccuparvi dei rischi di reazioni avverse. Inoltre, queste vitamine naturali sono utili per il vostro benessere over-all. Oltre a questi vantaggi benessere, disfunzione erettile vitamine naturali e integratori costano molto meno di farmaci rimedi. 4. Esercitare. Fai una mossa e non un tablet vibrante. Camminare farà di più per migliorare e sostenere hardons di qualsiasi altra compressa chimica nel lungo periodo. Il fitness fisico manterrà bassi livelli di pressione e mantenere grandi stadi di movimento. Andando per un 20-30 minuti di movimento rapido ogni giorno, può affrontare questo problema e può sostenere la vostra libido senza l uso di qualsiasi farmaco. 5. Sottolineare. Questo è il peggior attaccante per problemi di erezione. Scopri diversi metodi per riposare. Alcuni metodi tipici per riposare includono la lettura di un libro, la meditazione, un bagno rilassante o allenamenti di respirazione. Sto solo imparando alcuni semplici allenamenti di respirazione che possono migliorare significativamente il movimento nel reparto pantaloni. Una naturale disfunzione erettile soluzioni di trattamento stanno diventando sempre più popolare con gli uomini. Questi rimedi a base di erbe sono preferiti perché non hanno reazioni avverse e sono confermati essere efficiente come il farmaco. La maggior parte degli uomini combattere parlano dei loro problemi, in particolare la disfunzione erettile come c è poca discussione sui problemi di erezione. La verita e che ED ha un impatto su piu di dieci milioni di uomini solo negli Stati Uniti. Non siete soli e l aiuto è disponibile.
Microsoft word - pub_06082012.doc
Publikationsliste
Originalarbeiten
1. Ledergerber B., Bettex J-D., Joos B., Flepp M., Lüthy R. (1985) Effect of standard
breakfast on drug absorption and multiple-dose pharmacokinetiks of ciprofloxacin. Antimicrob. Agents Chemother. 27:350-353
2. Joos B., Hugentobler A., Ledergerber B., Flepp M., Bettex J-D., Lüthy R. (1985)
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob. Agents Chemother. 27:353-356
3. Münch R., Bühler H., Ammann R., Kehl O., Flepp M., Lüthy R., Vogt M.,
Siegenthaler W (1986) Gastrointestinale Beteiligung beim erworbenen Immunmangel- Syndrom (AIDS). Z. Gastroenterologie 24:235-244
4. Flepp M., Täuber M.G., Lüthy R. Frauchiger B., Barandun J., Schütze M. Joller H.,
Frey-Wettstein M., Vetter W., Siegenthaler W (1986) Transfusions-assoziierte Infektionen mit LAV/HTLV-III in der Schweiz. Schweiz. Med. Wschr. 116: 426-428
5. Lingenfelser T., Flepp M., Greminger P. (1986) Status febrilis, Husten, Kopf-
schmerzen. <Legionärskrankheit> [clinical conference]. Schweiz. Rundschau Med. (PRAXIS) 75:799-803
6. Garlando F., Rietiker S., Täuber M.G., Flepp M., Meier B., Lüthy R. (1987) Single-dose
ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in woman. Antimicrob. Agents Chemother. 31:354-356
7. Moradpour D., Flepp M., Frei E., Greminger P. (1987) Knieschmerzen, Fieber.
<Brodie-Abszess> [clinical conference]. Schweiz. Rundschau Med. (PRAXIS)
8. Flepp M., Täuber M.G., Lüthy R., Siegenthaler W. (1988) Kaposi's sarcoma in AIDS
patients: Long term treatment with recombinant interferon alpha-2a and
9. Flepp M., Rhyner K., Lüthy R., Greminer P., Vurma-Rapp U., Wolfisberg C.,
Burnens A., Siegenthaler W (1988) Mykobakteriosen bei Patienten mit HIV-Infektion. Dtsch. Med. Wschr. 113: 711-718
10. Adam H., Flepp M., Schüler G., Egli F., Greminger P., Lüthy R., Rhyner K. (1988)
Maligne Lymphome bei HIV-infizierten Patienten. Schweiz. Med. Wschr. 118:1651-1656
11. Steiner A., Flepp M., Vetter W. (1988) Schwäche, Erbrechen, Gewichtsverlust.
Bartter-Syndrom bei Laxantienabusus> [clinical conference]. Schweiz.
12. Vurma-Rapp U., Colla F., Flepp M. (1989) Mycobacterium kansasii and pneumocystis
carinii pneumonia in the acquired immunodeficiency syndrome. Infection 17:88-89
13. Flepp M., Lüthy R., Wüst J., Steinke W., Greminger P. (1989) Rhodococcus equi-
Infektion bei HIV-Krankheit. Schweiz. Med. Wschr. 119:566-574
Stillhard G., Turina M., Flepp M., Waespe W. (1991) Triparese bei bilateralen Anterior/Media-Wasserscheideninfarkten. Schweiz. Med. Wschr. 121:221-227
15. Flepp M., Herrmann P., Waespe W. (1991) Status febrilis, Cephalea und Parese des
linken Beines. <Subdurales Emypem mit Streptococcus milleri> [clinical conference]. Schweiz. Rundschau Med. (PRAXIS) 80:301-305
16. Heald A., Flepp M., Chave J-P., Maliniverni R., Rüttimann S., Gabriel V., Rénold C.,
Sugar A., Hirschel B. and the Swiss HIV cohort Study (1991) Treatment for cerebral toxoplasmosis protects against pneumocystis carinii pneumonia in patients with AIDS. Ann. Int. Med. 115;760-763
17. Pugin J., Vanhems P., Hirschel B., Chave J-P., Flepp M. (1992) Extreme elevations of
serum lactate dehydrogenase differentiating pulmonary toxoplasmosis from pneumocystis carinii pneumonia. N. Engl. J. Med. (Letter) 326:1226
18. Peter O., Flepp M., Bestetti G., Nicolet J., Lüthy R., Dupuis G. (1992) Q fever
endocarditis: diagnostic approaches and monitoring of therapeutic effects. J. Clin. Investig. 70:932-937
19. Biedermann K., Flepp M., Fierz W., Joller-Jemelka H., Kleihues P. (1995). Pregnancy,
immunosuppression and reactivation of latent toxoplasmosis. J. Perinat. Med. 23:191-203
20. Carbon C., Warell D., Aboulker JP., Cooper D.A., Darbyshire J., Dormont J., Flepp M.,
Lange J., Levy J-P., Mathiesen L., Peto T., Pinching A.J., Reiss P., Schwartz D., Seligmann M., Stone A., Thomis J., Withnall R., Barker S., Frissen J., de Jong M., Loewenthal M., Tournerie C., Valentine C., Aber V., Babiker A., Charreau I., Thakrar B., Vray M. [The Alpha International Coordinationg Committee] (1996) Alpha MRC/ANRS European/Australian randomised double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. AIDS 10:867-880
21. Van Delden A., Gabriel V., Sudre Ph., Flepp M., Von Overbeck J., Hirschel B. (1996)
Reasons for failure prevention of Toxoplasma encephalitis. AIDS 10:509-513
22. Schüpbach J., Flepp M., Pontelli M., Tomasik Z., Lüthy R., Böni J. (1996) Heat
mediated immunecomplex dissociation and ELISA signal amplification render antigen p24 detection in plasma as sensitive as HIV-1 RNA detection by polymerase chain reaction. AIDS 10:1085-1090
23. The Delta Coordinating Commitee [Aber V., Aboulker J-P., Babiker A.G., Bragman K.,
Breckenridge A.M., Carbon C., Charreau I., Chene G., Collis P., Cooper D., Darbyshire J.H., Dormont J., Fiddian P., Flepp M., Gazzard B., Goebel F.D., Hooker M., Lange J.,
Lüthy R., Peto T.E.A., Reiss P., Seligmann M., Stone A.B., Thomis J., Vella S., Walckenaer G., Warrell D., Weller I.V.D., Wilber R., Yeni P., Yeo J., Withnall R.] (1996) Delta: a ronadomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV indwcted individuals. Lancet 348:283-91
24. Weber R., Deplazes P., Flepp M., Mathis A., Baumann R., Sauer B., Kuster H., Lüthy
R. (1997) Cerebral Microsporidiosis Due to Encephalitozoon Cuniculi in a Patient with Human Immunodeficiency Virus Infection. N. Engl. J. Med. 336: 474-478
25. Gruner A., Flepp M., Gabathuler U., Thomg K.L., Altwegg M. (1997) Qutbreak of
typhoid fever in a non-endemic area: comparison of three molecular typing methods. J. Microbiol. Methods 28:179-185
26. Wiesli P., Flepp M., Greminger P. (1997) Fieber und trockener Husten bei einem
Bauarbeiter aus Portugal <Brucellosis> [clinical conference]. Schweiz. Rundschau Med. (PRAXIS) 86:1215-1219
27. Vernazza P.L., Gilliam B.L., Flepp M., Dyer J.R., Frank A.C., Fiscus S.A., Cohen M.S.,
Eron J.E. (1997) Effect of Antiretroviral Treatment on the Shedding of HIV-1 in Semen. AIDS 11:1249-1254
28. Weber R., Flepp M., Wichmann W. (1997) Disseminated microsporidial infection and
sinusitis in an HIV-infected patient. N. Engl. J. Med. (Letter) 337:640-641
29. Quinlivan A.B., Ye D., Wehbie R.S., Stewart P.W., Flepp M., Vernazza P.L. (1997)
Kaposi's sarcoma patients in the Swiss HIV Cohort Study with and without detectable Human Herpesvirus 8 in peripheral blood mononuclear cells. AIDS 11:1893-1895
30. Egger M., Hirschel B., Francioli P., Sudre Ph., Wirz M., Flepp M., Rickenbach M.,
Malinverni R., Vernazza P., Battegay M. and the Swiss HIV Cohort Study (1997) Marked decrease in progression and mortality of HIV infection in Switzerland. British Medical Journal 315:1194-9
31. Morawetz R.A., Rizzardi G.P., Glauser D., Rutschmann O., Hirschel B., Perrin L.,
Opravil M., Flepp M., von Overbeck J., Glauser M.P., Ghezzi S., Vicenzi E., Poli G., Lazzarin A., Pantaleo G. (1997) Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort. Eur. J. Immunol. 27(12):3223-7
32. Cameron W., Heath-Chiozzi M., Danner S., Cohen D., Kravcik S., Maurath C., Sun E.,
Henry D, Rode R., Potthoff A., Leonard J., for The Advanced Ritonavir Study Group (1998) Randomised placebo-controlled trial of ritonavir in advanced
33. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., Vernazza
P., Sudre Ph., Flepp M., Furrer Hj., Francioli P., Weber R. for the Swiss HIV Cohort Study. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353:863-868
34. Goebel F.D., Mannhalter J.W., Belshe R.B., Eibl M.M., Grob P.J., de Gruttola V.,
Griffiths P.D., Erfle V., Kunschak M., Engl W. and the European Multinational IMMUNO AIDS Vaccine Study Group. (1999) Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. AIDS 13:1461-1468
35. FurrerHj., Egger M., Opravil M., Bernasconi E., Hischel B., Battegay M., Telenti A.,
Vernazza P.L., Rickenbach M., Flepp M., Malinverni R. for the Swiss HIV Cohort Study. (1999) Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in HIV-1 Infected Adults Treated with Combination Antiretroviral Therapy. N. Engl. J. Med. 340:1301-6
36. Bassetti S., Battegay M., Furrer Hj., Rickenbach M., Flepp M., Kaiser L., Telenti A.,
Vernazza P.L., Bernasconi E., Sudre Ph., and the Swiss HIV Cohort Study. (1999) Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J. Acquir, Immune Defic. Syndr. 21:114-9
37. Weber R., Ledergerber B., Zbinden R., Altwegg M., Pfyffer G.E., Spycher M.A., Briner
J., Kaiser L., Opravil M., Meyenberger C., Flepp M. and the Swiss HIV Cohort Study (1999) Enteric Infections and Diarrhea in HIV infected Persons: Prospective Community based Cohort Study. Archives of Internal Medicine 159:1473-1480
38. The Delta Coordinating Commitee [Aber V., Aboulker J-P., Babiker A.G., Bragman K.,
Breckenridge A.M., Carbon C., Charreau I., Chene G., Collis P., Cooper D., Darbyshire J.H., Dormont J., Fiddian P., Flepp M., Gazzard B., Goebel F.D., Hooker M., Lange J., Mosconi G., Lüthy R., Peto T.E.A., Reiss P., Salgo M., Seligmann M., Stone A.B., Vella S., Walckenaer G., Warrell D., Weller I.V.D., Wilber R., Yeni P., Yeo J, Withnall R.] and Virology Group (1999) HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. Delta Coordinating Committee and Delta Virology Committee. AIDS 13:57-65
39. The Delta Coordinating Commitee [Aber V., Aboulker J-P., Babiker A.G., Bragman K.,
Breckenridge A.M., Carbon C., Charreau I., Chene G., Collis P., Cooper D., Darbyshire J.H., Dormont J., Fiddian P., Flepp M., Gazzard B., Goebel F.D., Hooker M., Lange J., Mosconi G., Lüthy R., Peto T.E.A., Reiss P., Salgo M., Seligmann M., Stone A.B., Vella S., Walckenaer G., Warrell D., Weller I.V.D., Wilber R., Yeni P., Yeo J, Withnall R.] and Virology Group (1999) An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 13:565-573
HIV Trialists‘ Collaborative Group [Abrams D., Allan D., Antunes F., Babiker A., Breckenridge A., Bruun J., Cameron W., Carbon C., Chalmers I., Chang H., Chodakewitz I., Clendenin N., Clumeck N., Collier A., Collins R., Collins G., Cooper E., Cooper D., Danner S., D'Aquila R., Darbyshire J., DeGruttola V., DeMasi R., Dee L., Deyton L., Dixon D., Dormont J., Duncan W., Farthing C., Feinberg J., Fischl M., Flepp M., Foulkes M., Gartland M., Gatell J., Gazzard B., Goebel F., Gotzsche P., Gringeri A., Hall D., Hamilton J., Hammer S., Hartigan P., Heath-Chiozzi M., Henry K., Hille A., Hirschel B., Hughes M., Ioannidis J., Kahn J., Katlama C., Katzenstein D., Killen J., King E., Kinloch de Loes S., Kravcik S., Lange J., Leavitt R., Leonard J., Maeland A., Mannucci P., Mathiesen L., McDade H., Meibohn A., Melander H., Merigan T., Mulder J., Myers M., Neaton J., Nessling M., Perrin L., Peto R., Peto T., Pettinelli C., Phair J., Phillips A., Pinching A., Poppa A., Power L., Reiss P., Richman D., Rooney J., Rousseau F., Rutherford G., Salgo M., Sande M., Sandstrom E., Saravolatz L., Savidge G., Schnittman S., Schooley R., Seligmann M., Simberkoff M., Skowron G., Slade P., Smith D., Smith R.P., Soriano V., Stanley K., Stingl G., Stoffels P., Struthers L., Tierney C., Thompson M., van der Broeck R., Van Leeuven R., Van Weverling G., Veenstra J., Vella S., Volberding P., Walker S., Weber J., Weller I., Winslow D., Yeni P., Yeo J.] (1999) Meta-analysis of the randomised evidence on zidovudine, didanosine and zalcitabine in the treatment of HIV infection. Lancet 353:2014-2025.
41. Paris D., Ledergerber B., Weber R., Jost J., Flepp M., Opravil M., Ruef C., Zimmerli S.
(1999) Incidence and predictors of virologic failure of antiretroviral triple drug therapy in a community based cohort. AIDS Res. Hum. Retrov. 15(18):1631-1638
42. Vernazza P.L., Troiani L., Flepp M.J., Cone R.W., Schock J., Roth F., Boggian K.,
Cohen M.S., Fiscus S.A., Eron J.J. and the Swiss HIV Cohort Study (2000) Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. AIDS 14:117-121
43. Ledergerber B., Flepp M., Böni J. Tomasik Z., Cone R., Lüthy R., Schüpbach J. (2000)
HIV-1 p24 concentration measured by boosted ELISA of heat-denaturated plasma corelates with CD4+ decline, progression to AIDS and survival: Comparison with viral RNA. J. Infect. Dis.181:1280-7.
44. Bürgisser P., Vernazza P.L., Flepp M., Böni J., Tomasik Z., Hummel U., Pantaleo G.,
Schüpbach J. and the Swiss HIV Cohortv Study (2000) Performance of five different assays for the quantification of viral load in subjects infected with various subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 23:138-144.
45. Somaini B., Wang J., Perozo M., Kuhn F., Meili D., Grob P., Flepp M. The Zurich
Prometheus Study Group. (2000) A continuing concern: HIV and hepattis testing and prevalence among drug users in substitutioin programs in Zurich, Switzerland. AIDS Care 12:449-460.
46. Schüpbach J., Tomasik Z., Nadal D., Ledergerber B. Flepp M., Opravil M. Böni J.
(2000) Use of HIV-1 p24 as a Sensitive, Precise and Inexpensive Marker for Infection, Disease Progression and Treatment Failure. Int J Antimicrobial Agents 16:441-445.
47. Greub G., Ledergerber B., Battegay M., Grob P., Perrin L., Hurrer Hj., Burgissser P.,
Erb P., Boggian K., Piffaretti J-C, Hirschel B., Janin P., Flepp M., Telenti A. and the Swiss HIV Cohort Study (SHCS). (2000) Impact of HCV Infection on HIV Progression, Survival and Immuine Recovery. The Swiss HIV Cohort Study. Lancet 356:1800-1805.
48. Friedl A.C., Jost C.H., Schalcher C., Amann F.W., Flepp M., Jenni R., Linka A., Weber
R. (2000). Acceleration of Confirmed Coronary Artery Disease among HIV-infected Patients on Potent Antiretroviral Therapy. AIDS 14:2790-2792.
49. The European Collaborative Study and the Swiss Mother and Child HIV Cohort Study [
Aebi C., Battegay M., Bernasconi E., Biedermann K., Cheseaux JJ., Drack G., Erb P., Flepp M., Francioli P., Furrer Hj., Gianinazzi MP., Gyr T., Hirschel B., Hösli I., Hug I., Irion O., Keller K., Kinde C., Laubereau B., Lauper U., Lorenzi P., Matter L., Nadal D., Perrin L., Rickenbach M., Rudin C., Schreyer A., Schüpbach J., Telenti A., Vernazza P- . Wolf K., Wunder D., Wyler AC.] (2000). Combination antiretroviral Therapy and Duration of Pregnancy. AIDS 14:2913-2920.
50. Furrer Hj., Opravil M., Rossi M., Bernasconi E., Telenti A., Bucher H., Schiffer V.,
Boggian K., Rickenbach M., Flepp M., Egger M. and the Swiss HIV Cohort Study. (2001) Discontinuation of Primary Prophylaxis in HIV-infected Patients at High Risk of Pneumocystis carinii Pneumonia: Prospective Multicentre Study. AIDS 15:501-507.
51. The Initio Coordinating Committee [Cooper D., Yeni P., Angarano G., Antunes F.,
Churchill D., Conway B., Flepp M., Lelekis M., Gatell J., Girarad PM., Hemmer R., Lundgren J., Mijch A., Mulcahy F., Ristola M., Salzberger B., Sandström E., Staszewski S., Weber J., De Wit S.] (2001) An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 Infection: Design, Rationale, and Methods of the Initio Trial. Controlled Clinical Trials 22:160-175.
52. The Delta Coordinating Commitee [Aber V., Aboulker J-P., Babiker A.G., Bragman K.,
Breckenridge A.M., Carbon C., Charreau I., Chene G., Collis P., Cooper D., Darbyshire J.H., Dormont J., Fiddian P., Flepp M., Gazzard B., Goebel F.D., Hooker M., Lange J., Mosconi G., Lüthy R., Peto T.E.A., Reiss P., Seligmann M., Stone A.B., Thomis J., Vella S., Walckenaer G., Warrell D., Weller I.V.D., Wilber R., Yeni P., Yeo J, Withnall R.] (2001) Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up. HIV Medicine 2:181-188.
53. Schüpbach J., Böni J., Flepp M., Tomasik Z., Joller H., Opravil M. (2001) Antiretroviral
treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA . J Med Virology, 65:225-232.
54. Roos F., Flepp M., Figueras G., Bodmer T., Furrer Hj and the Swiss HIV Cohort Study
(2001) Clinical manifestations and predictors of survival in AIDS patients with disseminated M.avium infection. EJCM, 20:428-442.
55. Battegay M., Vernazza P.L., Bernasconi E., Flepp M., Sendi P., Erb P., Malinverni R.,
Jaccard C., Morgenthaler S., Bedoucha V., Hirschel B., for the Swiss HIV Cohort Study. (2001) Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. HIV-medicine HIV Medicine 2:35-42.
56. Boubaker K., Flepp M., Sudre P., Furrer H., Haensel A., Hirschel B., Boggian K.,
Chave J-P., Bernasconi E., Egger M., Opravil M., Rickenbach M., Francioli P., Telenti A. for the Swiss HIV Cohort Study. (2001) Hyperlactatemia and Antiretrovrial Therapy: The Swiss HIV Cohort Study. CID 33:1931-7
57. Friedl A.C., Ledergerber B., Flepp M., Hirschel B., Telenti A., Furrer H.J., Bucher H.C.,
Bernasconi E., Weber R. for the Swiss HIV Cohort Study. (2001) Response to First Protease Inhibitor and Efavirenz Containing Antiretroviral Combination Therapy. The Swiss HIV Cohort Study. AIDS 15:1793-1800.
58. Yerly S., Vora S., Rizzardi P., Chave J-P., Vernazza P., Flepp M., Telenti A., Battegay
M., Veuthey A-L., Bru J-P, Rickenbach M., Hirschel B., Perrin L., and the Swiss HIV Cohort Study. (2001) Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15:2287-2292
59. Fellay J., Boubaker K., Ledergerber B., Bernasconi E., Furrer Hj., Battegay M., Hirschel
B., Vernazza P., Francioli P., Greub G., Flepp M., and Telenti A. for the SHCS (2001). Prevalence of clinical and laboratory adverse events associated with potent antiretrovial therapy – the Swiss HIV Cohort Study. Lancet 358:1322-27.
60. Hirschel B., Flepp M., Bucher H.C., Zellweger C., Telenti A., Wagels T., Ledergerber B
(2002). Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 16:1-381-5
61. Rossi M., Flepp M., Telenti A., Schiffer V., Egloff N., Bucher H., Vernazza P.,
Bernasconi E., Weber R., Rickenbach M., Furrer H., and the Swiss HIV Cohort Study (2001) Disseminated M.avium infection in the Swiss HIV Cohort Study: Declining incidence, improved prognosis and interruption of maintenance therapy. SMW 131:471-478.
62. Bernasconi E., Boubaker K., Junghans C., Flepp M., Furrer HJ., Haensel A., Hirschel
B., Boggian K., Chave JP., Opravil M., Weber R., Rickenbach M., Telenti A. (2002) Abnormalities of body fat distribution in HIV infected persons treated with antiretroviral therapy: The Swiss HIV Cohort Study. JAIDS 2002:31:50-55.
63. Eigenmann C., Flepp M., Bernasconi E. ,Schiffer V., Telenti A., Bucher H., Wagels T.,
Furrer Hj., and the Swiss HIV Cohort Study. (2003) Low incidence of community acquired pneumonia in HIV-infected patients who interrupt antibiotic primary prophylaxis against P. carinii pneumonia. Clin Infect Dis. 2003;36:917-21.
64. Hasse B, Hummel Y, Böni J, Schüpbach J, Flepp M, Günthard HF. (2003) 25-jähriger
therapienaiver Patient mit einem dreiklassenresistenten HI-Virus. Praxis 2003; 61:6101-605.
65. Siegl G. im Namen der SEVHEP. (2003) Hepatitis A-Virus-Infektion. Übersicht. Praxis
66. Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M,
Speck RF, Grube C, Rentsch K, Weber R, and Günthard HF, and the Swiss HIV Cohort Study. (2003) Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy 2003;8:443-454.
67. Jaggi C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, Furrer
H-J, Telenti A, Battegay M, Flepp M, Vernazza P, Bernasconi E, Hirschel B, and the Swiss HIV Cohort Study. (2003) Closing the Gap: Life Expectancy in the Swiss HIV Cohort Study (SHCS) Compared to the Swiss Reference Population. Lancet 2003;362:877-878.
68. Furrer H, Battegay M, Spirig R, Flepp M und die Swiss HIV Cohort Study (2003)
Herausforderungen bei der HIV-Langzeitbetreuung. DMW 2003;128:1064-1069.
69. Böni J, Shah C, Flepp M, Lüthy R, Schüpbach J. (2003) Detection of low copy numbers
of HIV-1 proviral DNA in patient PBMC by a high-input, sequence-capture PCR (Mega-PCR). Journal of Medical Virology 2003:9999:1-9.
70. Wolf K., Young J, Rickenbach M, Vernazza P., Flepp M, Furrer Hj, Bernasconi E,
Hirschel B, Telenti A, Weber R, Bucher HC, for the Swiss HIV Cohort Study. Prevalence of unsafe sexual behavior among HIV-infected individuals: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2003;33:494-499.
71. Young J, De Geest S, Spirig R, Flepp M, Rickenbach M, Furrer H, Bernasconi E,
Hirschel B, Telenti A, Vernazza P, Battegay M, Bucher H for the Swiss HIV Cohort Study. Stable partnership and progression to AIDS or death in HIV-infected individuals receiving highly active antiretroviral therapy: The Swiss HIV Cohort Study SHCS. BMJ. 2004;328:15
72. Fellay C, Morris MA, Wonkam A, Hirschel B, Flepp M, Wolf K, Furrer H, Battegay M,
Bernasconi E, Telenti A, Frossard JL. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 2004;18:1521-7.
73. Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, Egger M,
Guyot S, Hirschel B, Weber R, Gunthard HF; Swiss HIV Cohort Study. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. AIDS Res Hum Retroviruses. 2004;20:909-15.
74. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, Vernazza P, Battegay M,
Furrer H, Chanzy B, Burgisser P, Rickenbach M, Gebhardt M, Bernard MC, Perneger T, Hirschel B, Perrin L; Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther. 2004 Jun;9(3):375-84.
75. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Gunthard
HF, Trkola A. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology. 2004;326:113-29.
76. Strub C, Kaufmann GR, Flepp M, Egger M, Kahlert C, Cavassini M, Battegay M; Swiss
HIV Cohort Study. Gynecomastia and potent antiretroviral therapy. AIDS 2004;18:1347-9.
77. Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM,
Boni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF; Swiss HIV Cohort Study. HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load. J Infect Dis. 2004;189:1199-208.
78. Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Wagels T,
Flepp M, Rickenbach M, Furrer H; Swiss HIV Cohort Study. Long-term
discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS. 2004;18:2047-53.
79. Hurlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, Kobza R, Muntwyler
J, Ledergerber B, Luscher TF, Noll G, Weber R. Effects of HMG-CoA reductase inhibition on endothelial function and lipid profile in HIV-infected persons on protease inhibitor-containing antiretroviral combination therapy: a randomized double-blind cross-over trial. Heart. 2006 ; 92:110-2. Epub 2005 Mar 29
80. Bertschy S, Opravil M, Cavassini M, Bernasconi E, Schiffer V, Schmid P, Flepp M,
Chave JP, Christen A, Furrer H; Swiss HIV Cohort Study. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clin Microbiol Infect. 2006;12:666-71.
81. Buehlmann M, Chave JP, Flepp M, Schiffer V, Keiser O, Furrer H. Tenofovir-containing
nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. HIV Clin Trials. 2006;7:48-54.
82. Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Gunthard HF,
Bonhoeffer S. HIV replication elicits little cytopathic effects in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. J Med Virol. 2006;78:1141-6.
83. INITIO Trial International Co-ordniationg Committee (D A Cooper (joint chair NCHECR), P Yeni (joint chair Groupe Hospitalier Bichat). J-P Aboulker (INSERM SC10), F Antunes (national principal investigator, Portugal), A Babiker (MRC CTU), M Becker (Roche), N Boukli (INSERM SC10), F Brun-Vezinet (joint chair Virology group), D Carey (NCHECR), D Churchill (joint national principal investigator, UK), B Conway (national principal investigator, Canada), C Chazallon (INSERM SC10), J Darbyshire (MRC CTU), S De Wit (national principal investigator, Belgium), B Dusak (Dupont), S Emery (NCHECR), M Flepp (national principal investigator, Switzerland), M Floridia (ISS), J Gatell (national principal investigator, Spain), P-M Girard (national principal investigator, France), R L Goodall (MRC CTU), R Hemmer (national principal investigator, Luxembourg), M Hooker (MRC CTU), M Law (NCHECR), C Loveday (joint chair Virology Group) J Lundgren (national principal investigator, Denmark), D Manion (Dupont), V Mei. Redy (INSERM SC10), A Mijch (national principal investigator, Australia and New Zealand), F Mulcahy (National Principal Investigator, Ireland), A Orani (national principal investigator, Italy), C Pharo (GSK), M Ristola (national principal investigator, Finland), B Salzberger (joint national principal investigator, Germany), E Sandstrom (national principal investigator, Sweden), M Schechter (national principal investigator, Brazil), S Schnittman (Bristol Myers Squibb), M Seligmann (chair immunology group), S Staszewski (joint national principal investigator, Germany), M Stek (Merck), W Verbiest (VIRCO), J Weber (joint national principal investigator, UK), R Withnall (Secretary). G Kotsiou, P Pigott), Royal Prince Alfred Hospital, Sydney (R Garsia, M Moussa, C O’Connor), St Leonards Medical Centre, Sydney) Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368: 287-298.
Taffe P, Bucher HC, Flepp M, Battegay M. Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era. AIDS 2007;21:537-8.
85. Rotger M, Saumoy M, Zhang K, Flepp M, Sahli R, Decosterd L, Telenti A and the
Swiss HIV Cohort Study. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenetics and Genomics 2007,17:885–890.
86. Vernazza P., Hirschel B., Bernasconi E., Flepp M. HIV transmission under highly
active antiretroviral therapy [author replay]. Lancet 2008, 372;1806.
87. Dang T, Jaton-Ogay K, Flepp M, Kovari H, Evison JM, Fehr J, Schmid P, Boffi El
Amari E, Cavassini M, Odorico M, Tarr PE, Greub G. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. Clin Infect Dis. 2009 Nov 15;49(10):1532-5.
88. Bihl F, Berger C, Chisholm JV 3rd, Henry LM, Bertisch B, Trojan A, Nadal D, Speck
RF, Flepp M, Brander C, Mueller NJ; Swiss HIV Cohort Study Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS. 2009 Sep 10;23(14):1918-22.
89. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, Mueller NJ,
Muellhaupt B, Weber R; Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 2009 Aug 15;49(4):626-35.
90. Magenta L, Dell-Kuster S, Richter WO, Young J, Hasse B, Flepp M, Hirschel B,
Vernazza P, Evison J, Cavassini M, Decosterd LA, Bucher HC, Bernasconi E; the Swiss HIV Cohort Study (SHCS). Lipid and Lipoprotein Profile in HIV-Infected Patients
Treated with Lopinavir/Ritonavir as a Component of the First Combination
Antiretroviral Therapy. AIDS Res Hum Retroviruses 2011;27:525-33. doi:
10.1089/aid.2010.0207. Epub 2010 Nov 22.
91. Weber R, Ruppik M, Rickenbach M, Spörri-Fahrni A, Furrer Hj, Battegay M, Cavassini
M, Hirschel B, Bernasconi E, Flepp M, Lundgren J, Ledergerber B, and the Swiss HIV Cohort Study (SHCS). Causes auf death in the Swiss HIV Cohort Study: Changing patterns and methodological challenges. HIV Medicine 2012 (accepted) Übersichtsarbeiten
1. Flepp M., Täuber M.G. (1986) Opportunistische Infektionen bei Patienten mit HIV-
Infektion. Schweiz. Med. Rundschau (PRAXIS) 75:1445-1450
2. Colla F., Flepp M., Rietiker S., Jost J., Täuber M.G., Lüthy R. (1986) Epidemiologie
und Klinik der HIV- (Human Immunodeficiency Virus) Infektion. Labor und Medizin 13:584-595
3. Lüthy R., Täuber M.G., Rietiker S., Flepp M., Colla F. (1987) HIV-assoziierte
Krankheiten. Der informierte Arzt 8: 22-31
4. Flepp M., Täuber M.G., Lüthy R. (1988): Klinische Aspekte HIV-assoziierter
Krankheiten. Therapeutische Umschau 45: 604-610
5. Flepp M. (1997) HIV-Postexpositionsprophylaxe – Grenzen und Möglichkeiten.
Jahresbericht der Zürcher AIDS-Hilfe 1997
6. Flepp M., Levi G. (1998) Contrasts in managing opportunistic infections in HIV disease
between Europe and South America. Int. J. Clin. Pratice (Suppl 95);54
7. Flepp M. (1998) HIV und Internet – eine unvollständige Übersicht. infomed-screen 2:64
8. Flepp M. (2000) AZT-Kurzregime zur Verhinderung der perinatalen HIV-Transmission.
9. Flepp M., Schiffer V., Weber R., Hirschel B. (2001). Modern Anti-HIV Therapy. Swiss
10. Flepp M, Ledergerber B. The Swiss HIV Cohort Study--multifaceted network
supporting patient care as well as large international research projects. Ther Umsch. 2004;61:635-8.
11. Flepp M, HIV-Infektion: Aktuelle Therapieprinzipien. Aktuelle Medizin 2010;32:7-9. Buchbeiträge
1. Lüthy R., Täuber M.G., Rietiker S., Flepp M., Colla F. (1987) HIV-assoziierte
Krankheiten. In: Aktuelle Aspekte der Infektiologie. Siegenthaler W. (Hrsg), pp. 38-46, Georg Thieme Verlag: Stuttgart, New York
2. Lüthy R., Flepp M., Täuber M.G. (1987) Langzeitbehandlung des Kaposi-Sarkoms mit
Interferon alfa-2a. In: Therapie des Kaposi-Sarkoms mit rekombinantem alfa-Interferon. Dietrich M. (Hrsg), pp. 67-72, Wissenschaftliche Berichte des Tropen-instituts Hamburg, Hamburg
3. Flepp M. (1990) Mykobakterien bei AIDS-Patienten. In: Mykobakteriologie, Basler
Symposium 29.3.1990 Wehrle H. (Hrsg), Editiones Roche: Basel
4. Flepp M. (1991) Opportunistische Infektionen. Rationales diagnostisches Vorgehen. In:
Die HIV-Erkrankung. Medizinische und psychosoziale Aspekte zu Beginn der 90er Jahre. 2. Münchner AIDS-Tage. Jäger H. (Hrsg), pp. 57-60, Ecomed Verlag: Landsberg
5. Flepp M., Siegenthaler W. (1991) Opportunistische Infektionen. Therapie und
Prophylaxe. In: Die HIV-Erkrankung. Medizinische und psychosoziale Aspekte zu Beginn der 90er Jahre. 2. Münchner AIDS-Tage. Jäger H. (Hrsg), pp. 61-63, Ecomed Verlag: Landsberg
6. Flepp M. (1993) HIV-Erkrankung: Diagnostik - Stand des Wissens. In: AIDS:
Eine Krankheit wird behandelbar. Materialien zur HIV-Erkrankung im 2. Jahrzehnt. 3. Münchner AIDS-Tage. Jäger H. (Hrsg), pp. 63-67, Ecomed Verlag, Landsberg
7. Flepp M. (1993) Toxoplasmose und Zytomegalie - Diagnose und Therapie, heutiger
Stand. In: AIDS: Eine Krankheit wird behandelbar. Materialien zur HIV-Erkrankung im 2. Jahrzehnt. 3. Münchner AIDS-Tage. Jäger H. (Hrsg), pp. 95-100, Ecomed Verlag, Landsberg
8. Flepp M. (1996) Update der antiretroviralen Therapie. In: 26. Hämophiliesymposium,
Hamburg 1995. Scharrer I., Schramm W. (Hrsg.) pp. XX, Springer Verlag: Hamburg
9. Flepp M. (1997) Update der antiretroviralen Therapie der HIV-Infektion. In: 27.
Hämophiliesymposium, Hamburg 1996. Scharrer I., Schramm W. (Hrsg.), pp. XX, Springer Verlag: Hamburg
10. Schupbach J., Tomasik Z., Böni J., Nadal D., Flepp M., Ledergerber B., Opravil M.,
Cone R. (1999) Use of HIV-1 p24 as sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. Proceedings of the Fourth European Conference on Experimental AIDS Research, EACAR’99, Tampere, Finland. Monduzii Editore S.p.A. Bologna 1999: 157-162.
11. Flepp M., Jost J. Hirschel B., Weber R., Bernasconi E. für die Subkomission Klinik der
Eidgnössischen Komission für AIDS-Fragen. Empfehlungen zur antoretroviralen Therapie 2001, Kap XIV-1.7 1-9 in Jäger H. Aids und HIV-Infektion 33. Erg.Lfg 6/01 Ecomed Verlag, Landsberg
Andere Arbeiten:
1. Flepp M. (1986) Wie lautet Ihre Diagnose? <Kaposi-Sarkome bei AIDS-Patienten>
Schweiz. Rundschau Med. (PRAXIS) 75:601-602
2. Flepp M., Lüthy R. (1987) Soorbefall der Speiseröhre. Dtsch. Med. Wschr. 112:239-
3. Flepp M., Martenet A.C (1991) Wie lautet Ihre Diagnose? <Zytomegalieretinitis>
Schweiz. Rundschau Med. (PRAXIS) 80:315-316
4. Flepp M. (1991) Wie lautet Ihre Diagnose? <oral hairy leukoplakia> Schweiz.
5. Der HIV-Antikörpertest. Grundsatzpapier der Aidskommission des Kantons Zürich vom
6. Subkommission Klinik [SKK] der Eidgenössischen Kommission für AIDS-Fragen
[EKAF] (1992) Kapitel VI, AIDS und andere HIV-assoziierte Krankheiten - eine aktualisierte Übersicht, BAG-Ordner Infektionskrankheiten, 1992
7. Flepp M. (1992) Glossar Comic Jo (Aktualisierung und Überarbeitung für die deutsche
Fassung) In: Jo, Derib, Fondation pour la Vie. La Tour-de Peilz, Genève, Bruxelles 1992
8. Flepp M., Perrin L., Yerly S., Kinloch S., Wyler C.A. (1994) Zusammenfassung des
Second International Congress on Drug Therapy in HIV Infection Glasgow, Scotland 18-22. Novemvber 1994
9. Desgrandchamps D., Flepp M. (1994) Sanford 1994/1995. Leitfaden der anti-
mikrobiellen Behandlung. Übersetzung und Adaptation für die Schweiz von: Sanford J.P., Gilbert D.N., Gerberding J.L., Sande M.A. Guide to Antimicrobial Therapy 1994, Hyde Park, USA, 1994
10. Flepp M. (1994) Zidovudin bei asymptomatischen HIV-Patienten? Dtsch. Med. Wsch.r
Bundesamt für Gesundheitswesen, Eidgenössische Kommission für Aids-Fragen [EKAF] (1996) HIV-Übertragungsrisiko bei orogentialen Sexualpraktiken und daraus abzuleitende Präventionsempfehlungen. Bulletin des Bundesamtes für Gesundheit 3:8-9 (29. Januar 1996)
12. Desgrandchamps D., Flepp M. (1996) Sanford 1996/1997. Leitfaden der anti-
mikrobiellen Behandlung. Übersetzung und Adaptation für die Schweiz von: Sanford J.P., Gilbert D.N., Gerberding J.L., Sande M.A. Guide to Antimicrobial Therapy 1996, Hyde Park, USA, 1996
13. Flepp M., Jost J., Malinverni R., Vernazza P., Battegay M., Bernasconi E.,
Hirschel B. für die Subkommission Klinik [SKK] der Eidgen. Kommission für Aids Fragen [EKAF] (1997) Neue Empfehlungen zur Behandlung der HIV-Infektion bei Erwachsenen. Bulletin des Bundesamtes für Gesundheit 20:9-10 (26. Mai 1997)
14. Bernasconi E., Battegay M., Vernazza P., Flepp M. für die Subkommission Klinik
[SKK] der Eidgen. Kommission für Aids-Fragen [EKAF] (1997) Vorläufige Empfehlungen zur HIV-Postexpositionsprophylaxe ausserhalb des Medizinalbereichs. Bulletin des Bundesamtes für Gesundheit 50:4-8. (22. Dezember 1997)
15. Jost J., Flepp M., Vernazza P., Battegay M., Kaiser L., Weber R., Bernasconi E. für
die Subkommission Klinik [SKK] der Eidgenössischen Kommission für Aidsfragen [EKAF] (1998) Antiretrovirale HIV-Therapie: Empfehlungen 1998. Bulletin des Bundesamtes für Gesundheit 44, 5-9.
16. Flepp M., Meister T. (1998) Sanford 1998/1999. Leitfaden der antimikrobiellen
Behandlung. Übersetzung und Adaptation für die Schweiz von: Gilbert D.N., Moellering R.C. Jr., Sande M.A. Guide to Antimicrobial Therapy 1998, Hyde Park, USA, 1998
17. Flepp M., Jost J., Vernazza P., Bernasconi E. für die Subkommission Klinik [SKK] der
Eidgenössischen Kommission für Aidsfragen [EKAF] (1999) Präventionsempfehlungen zur Reduktion des HIV-Übertragungsrisikos bei orogenitalen Sexualpraktiken behalten ihre Gültigkeit. Bulletin des Bundesamtes für Gesundheit 11:210-211 (15. März 1999)
18. Desgandchamps D., Flepp M., Meister T. (2000) Sanford 2000/2001. Leitfaden der
antimikrobiellen Behandlung. Übersetzung und Adaptation für die Schweiz von: Gilbert D.N., Moellering R.C. Jr., Sande M.A. Guide to Antimicrobial Therapy 2000, Hyde Park, USA, 2000.
19. Grob P.J., Joller Jemelka H.I., Flepp M., Schanz U., Schüpbach J. Diagnostik der HIV-
20. Flepp M., Jost J., Hischel B., Weber R. , Bernasconi E. für die Subkommission Klinik
[SKK] der eidgenössischen Kommission für Aidsfragen [EKAF] (2000): Empfehlungen zur antiretroviralen HIV - Therapie 2001. Bulletin des Bundesamtes für Gesundheit 51:994-1000 (18. Dezember 2000).
21. Bürki B., Flepp M., Saller R., Tuchschmid A., Hüsler G.(1995-2000) Behandlungs-
möglichkeiten bei HIV und AIDS Aids-Info Docu, Schweiz, 1995-2000.
22. Flepp M., Schiffer V., Weber R., Hirschel B. Modern Anti-HIV Therapy. Swiss Med
23. Warum erkrankten HIV-infizierte Menschen im Zeitalter der Primärprophylaxe an einer
Pneumocystis carinii Pneumonie? Inaugural-Dissertation zur Erlangung der Doktor- würde der Medizinischen Fakultat der Universität Zürich, vorgelegt von Christine Barbara Schenker, Arbeit unter der Leitung von Markus Flepp, genehmigt auf Antrag von Prof. W. Vetter, Zürich 2001.
24. Desgandchamps D., Flepp M., Meister T. (2002) Sanford 2002/03. Leitfaden der anti-
mikrobiellen Behandlung. 5. Adaptierte Version für die Schweiz. Übersetzung und Adaptation von: Gilbert D.N., Moellering R.C. Jr., Sande M.A. Guide to Antimicrobial Therapy 2002, Hyde Park, USA, 2002.
25. Desgandchamps D., Flepp M., Meister T. (2004) Sanford 2004/05. Leitfaden der anti-
mikrobiellen Behandlung. 6. Adaptierte Version für die Schweiz. Übersetzung und Adaptation von: Gilbert D.N., Moellering R.C. Jr., Eliopoulos G.M., Sande M.A. Guide to Antimicrobial Therapy 2004, Hyde Park, USA, 2004.
26. Fachkomission Klinik und Therapie HIV/AIDS (FKT) et al. Schwangerschaft und HIV:
Empfehlungen der FKT zur Prävention der vertikalen Transmission. Bulletin des Bundesamtes für Gesundheit 53:1008-11 (27. Dezember 2004).
Fachkomission Klinik und Therapie HIV/AIDS (FKT). Empfehlung zur HIV-Post-expositionsprophylaxe ausserhalb des Medizinalbereichs – Update 2006. Bulletin des Bundesamtes für Gesundheit 26:712-15 (04. September 2006).
28. Vernazza P. Hirschel B. Bernasconi E., Flepp M. (EKAF). HIV infizierte Menschen
ohne andere STD ind unter wirksamer antiretroviraler Therapie sexuell nicht infektiös. Schweizerische Ärztezeitung 2008; 89:165-69
29. Rudin C., Nadal D., Hösli I., Flepp M. Für die Fachkomsiion Klinik und Therapie
HIV/AIDS. HIV, Schwangerschaft und Geburt. Ein Update der Empfehlungen zur Prävention der vertikalen Transmission. Bulletin des Bundesamtes für Gesundheit 5:69-73 (26. Januar 2009).
30. Flepp M., Cavassini M., Vernazza P., Furrer HJ., für die Fachkommission Klinik und
Therapie HIV/Aids (FKT). Der HIV-Test auf Initiative des Arztes: Empfehlungen ur Durchführung bei Erwachsenen. Bulletin des Bundesamtes für Gesundheit 11:264-366 (15. März 2010).
Common Chemotherapeutic Drugs Used in the Treatment of Breast Cancer Generic (Brand) Adverse Reactions Manufacturer * Not all patients will experience Indications Classification Precautions (Manufacturer’s website addresses are provided when known) Hormone antagonist Fetal harm to pregnant Nausea, vomiting, peripheral coagulation Diarrhea, vomiting, stomat
17_17 NEWS PARKING 17-04-2007 12:01 Pagina 17Combinazione vincente Da due strutture preesistenti eccone una terza, appenarealizzata, con le caratteristiche modulari del sistema Fast ParkAmmonta a 1.380.000 euro il finanziamento peril parcheggio di scambio multipiano che saràI lavori inizieranno a settembre. L’uso delrealizzato entro il 2008 a Roviano, comune inpa